Cyclacel Pharma (NASDAQ: CYCC) reported Q2 EPS of ($0.44), $0.06 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $370 thousand versus the consensus estimate of $0 .

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.